The effect of immunoadsorption with the Immusorba TR‐350 column on coagulation compared to plasma exchange. Issue 1 (14th August 2014)

• Record Type: Journal Article
• Authors: Koessler, J.; Kobsar, A.; Kuhn, S.; Koessler, A.; Yilmaz, P.; Weinig, E.; Putz, E.; Boeck, M.; Klinker, E.
• Is Part Of: Vox sanguinis. Volume 108:Issue 1(2015)
• Page Start: 46
• Page End: 51
• Publication Date: 2014-08-14
• Subjects: Blood -- Periodicals; Blood -- Transfusion -- Periodicals; Immunohematology -- Periodicals; Immunopathology -- Periodicals; 615.39
• DOI: 10.1111/vox.12191
• Languages: English
• ISSNs: 0042-9007

Abstract

<abstract abstract-type="main" id="vox12191-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="vox12191-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>Plasma exchange (PE) and immunoadsorption with the Immusorba TR‐350 column (IA) are used to remove autoantibodies from plasma in acute neurological autoimmune disorders. The impact of IA on coagulation and on low molecular weight heparin (LMWH) levels in comparison with PE was investigated.</p> </sec> <sec id="vox12191-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p>In five patients with neurological autoimmune disorders, coagulation parameters (global tests, coagulation factors) were measured before and after PE or IA (Part A). In five other patients under anticoagulation with LMWH, anti‐Xa activity and global tests were measured before and after the treatments (Part B).</p> </sec> <sec id="vox12191-sec-0003" sec-type="section"> <title>Results</title> <p>After PE, coagulation factors were significantly reduced by 50–70%. After IA, a distinct reduction was observed for fibrinogen, but not for antithrombin and most of the other coagulation factors. Anti‐Xa activity was reduced after PE (from 0·57 ± 0·10 to 0·13 ± 0·05 IU/ml) and almost unchanged after IA.</p> </sec> <sec id="vox12191-sec-0004" sec-type="section"> <title>Conclusion</title> <p>It is advisable to discontinue or to reduce LMWH doses and to monitor coagulation parameters and anti‐Xa activity after PE or IA to decide about further LMWH dosing.</p> </sec> </abstract>